[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.178.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 26, 2001

Salmeterol and Inhaled Corticosteroids in Patients With Persistent Asthma

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(24):3075-3078. doi:10.1001/jama.286.24.3075

To the Editor: In their study comparing the efficacy of inhaled corticosteroids (ICs), salmeterol monotherapy, and placebo,1 Dr Lazarus and colleagues concluded that it is probably unsafe to switch patients with moderate persistent asthma from ICs to monotherapy with salmeterol. Some patients received placebo, and all patients received a placebo during a 6-week run-out period at the end of the study. Although the study protocol was approved by a federal protocol review committee and the institutional review boards at each of the clinical sites, the report did not fully address several complex and controversial ethical issues in the study design.

First Page Preview View Large
First page PDF preview
First page PDF preview
×